ParaZero Technologies Ltd. — Form 20-F Summary
Business context and reporting period
ParaZero Technologies Ltd. is an Israeli aerospace company developing and selling autonomous parachute safety systems for commercial drones and unmanned aerial systems. Its principal product family, SafeAir, detects critical flight failures and deploys a parachute, with applications across commercial, industrial, defense and urban-air-mobility markets.
The filing is an annual Form 20-F for the fiscal year ended December 31, 2023, filed March 21, 2024. It reports under U.S. GAAP in U.S. dollars. The filing does not provide separate fourth-quarter financial statements; the requested “2023 Q4” information is therefore summarized within the full-year filing.
Financial results and key metrics
| US$ | 2023 | 2022 | Change |
|---|---|---|---|
| Sales | 620,508 | 560,118 | +10.8% |
| Gross profit | 143,898 | 222,553 | -35.3% |
| Gross margin | 23.2% | 39.7% | -16.5 percentage points |
| Operating loss | (2,799,604) | (1,838,610) | Loss increased 52.3% |
| Net loss | (3,771,379) | (1,653,038) | Loss increased 128.1% |
| Basic and diluted loss per share | (0.77) | (0.49) | Higher loss per share |
| Cash used in operating activities | (2,938,300) | (1,971,635) | Use increased 49.0% |
| Cash used in investing activities | (25,757) | (9,725) | Higher equipment spending |
| Cash provided by financing activities | 10,302,656 | 2,038,142 | Material increase |
Gross margin declined primarily because cost of sales increased 41.2%, including higher sales volume and approximately $33,000 of inventory write-downs. Operating expenses included research and development of $636,801, sales and marketing of $487,904, general and administrative expenses of $1,472,872, and IPO expenses of $345,925.
General and administrative expense increased 92.1%, reflecting higher labor, professional services, directors’ and officers’ insurance, and public-company compliance costs. Sales and marketing expense increased 84.3%, primarily from additional labor, subcontractors, travel and conferences. Research and development expense was broadly unchanged.
Reported net loss included significant non-cash or financing-related items: a $504,976 fair-value expense on convertible notes converted at the IPO, a $277,600 change in fair value of derivative warrant liabilities, $247,129 of issuance expenses allocated to warrant liabilities, and $152,745 of related-party loan interest expense.
Balance sheet, liquidity and capitalization
- Cash and cash equivalents were $7.43 million at December 31, 2023, compared with $89,806 at December 31, 2022.
- Total current assets were $8.37 million and total current liabilities were $755,086, implying current assets substantially exceeded current liabilities at year-end.
- Total assets were $8.42 million, compared with $1.15 million in 2022.
- Shareholders’ equity was $6.11 million at year-end, versus a deficit of $1.64 million in 2022. Accumulated losses were $18.42 million.
- The company had $1.56 million of derivative warrant liabilities and $399,794 of related-party loan liabilities at December 31, 2023. The Medigus credit facility of $745,000 was repaid after the IPO in August 2023.
- The July 2023 IPO generated $7.8 million of gross proceeds. The October 2023 PIPE generated approximately $5.1 million of gross proceeds before fees and expenses.
- At December 31, 2023, 10,073,956 ordinary shares were outstanding. The company subsequently increased authorized share capital to 200 million ordinary shares in January 2024.
Management stated that year-end cash, anticipated revenue from existing purchase orders and projected revenue from new customers were expected to fund current operations through the end of 2025. Management also expects to require additional capital to develop and commercialize its next-generation flight computer, including algorithm optimization, artificial intelligence and optical-sensor integration.
Material changes versus the prior comparable period
- Revenue increased 10.8%, reflecting a shift toward OEM integration sales and recurring customer relationships.
- Gross profit declined despite higher sales because cost of sales grew substantially faster than revenue.
- Operating expenses increased materially, especially sales and marketing and general and administrative costs, as the company expanded commercialization activities and became a Nasdaq-listed public company.
- Net loss more than doubled, primarily because of higher operating expenses and 2023 non-cash fair-value expenses associated with convertible notes and warrants.
- Operating cash burn increased to $2.94 million from $1.97 million, while financing inflows increased substantially because of the IPO and PIPE.
- Convertible notes or SAFEs totaling approximately $1.51 million converted into 504,976 ordinary shares upon completion of the IPO.
- The PIPE included pre-funded warrants and Series A and Series B warrants. Series A warrants were classified as liabilities; remaining pre-funded and Series B warrants were exercised on a cashless basis in January 2024.
Guidance, outlook, risks and unusual items
The company has not issued formal revenue or earnings guidance in the filing. Management expects continued losses and increased spending on research and development, sales, marketing, hiring, manufacturing capabilities and public-company compliance. The company remains in an early commercialization stage and has not generated significant revenue from its current products.
- Funding risk: Continued operating losses and negative operating cash flow mean the company may need additional debt or equity financing. Future financing could be unavailable, costly or dilutive.
- Nasdaq listing risk: The company received a February 2024 notice regarding non-compliance with Nasdaq’s $1.00 minimum bid-price requirement and had until August 6, 2024 to regain compliance, subject to possible additional procedures.
- Regulatory risk: Sales depend on aviation-authority approvals and evolving rules governing drone operations, including FAA, EASA and other national requirements.
- Commercialization and competition: OEM sales cycles may last months or years, demand is difficult to forecast, and competitors may develop lower-cost or higher-performing alternatives.
- Manufacturing and product-liability risk: The company relies on a limited supplier base for components, including parachutes, and defective or recalled safety products could result in significant costs, liability and reputational harm.
- Israel-related risk: Operations and substantially all personnel are located in Israel. The company reported no operational disruption from the Israel-Hamas war through the filing date, but prolonged or expanded hostilities, military reserve call-ups or supply-chain disruption could adversely affect operations.
- Government grant obligations: The company received approximately $748,000 of royalty-bearing Israel Innovation Authority grants and reported contingent liabilities of approximately $613,000. Royalties generally range from 3% to 3.5% of eligible product sales, with restrictions on transferring funded technology or manufacturing outside Israel.
- Internal controls: Management concluded that disclosure controls and procedures were not effective as of December 31, 2023 and identified material weaknesses involving segregation of duties, documentation, approvals, access reviews, vendor-control assessments and written accounting and IT policies.
- PFIC uncertainty: The company stated it may have been a passive foreign investment company for U.S. tax purposes in 2023 and has not determined its status for 2024 or later years.
Most important facts for investors to verify
- Whether the company’s cash balance and operating plan support operations through the end of 2025, given the $2.94 million 2023 operating cash burn and expected additional product-development spending.
- Whether revenue growth from OEM integrations and recurring sales can improve gross margins from the 2023 level of 23.2%.
- The status of Nasdaq minimum-bid-price compliance and any subsequent reverse split, financing or delisting proceedings.
- The fully diluted share count, including outstanding Series A warrants, other warrants and 366,172 unvested options, and the resulting potential dilution.
- Progress in remediating the disclosed material weaknesses in internal control over financial reporting.
- Regulatory approvals, certifications and customer adoption supporting SafeAir, SmartAir Trinity and the proposed counter-UAS business.
- Actual royalty obligations to the Israel Innovation Authority and any required approvals for overseas manufacturing, technology transfers or future corporate transactions.
- Whether the potential 2023 PFIC status creates additional U.S. tax reporting or economic consequences for U.S. investors.